Skip to main content
Marcela Maus, MD, Oncology, Boston, MA

MarcelaValderamaMausMDPhD

Oncology Boston, MA

Hematologic Oncology, Melanoma

Director of Cellular Immunotherapy, MGH Cancer Center, Faculty of Medicine, Harvard Medical School

Dr. Maus is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Maus' full profile

Already have an account?

  • Office

    Massachusetts General Hospital
    55 Fruit Street
    Boston, MA 02114

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2012
  • University of Pennsylvania Health System
    University of Pennsylvania Health SystemResidency, Internal Medicine, 2006 - 2008
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2005

Certifications & Licensure

  • MA State Medical License
    MA State Medical License 2015 - 2026
  • PA State Medical License
    PA State Medical License 2006 - 2016
  • NY State Medical License
    NY State Medical License 2008 - 2013

Publications & Presentations

PubMed

Journal Articles

  • Making CAR T Cells a Solid Option for Solid Tumors  
    Marcela Maus, MD, Frontiers in Neurology
  • Immunotherapy for Glioblastoma: Adoptive T-cell Strategies  
    Marcela V Maus, Carl H June, Clinical Cancer Research

Abstracts/Posters

  • Exploiting the Zinc Finger Degrome Targeted By Lenalidomide to Engineer Reversible Off-Switch Degradable Chimeric Antigen Receptors
    Marcela V Maus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Use of CD70 Targeted Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Acute Myeloid Leukemia (AML)
    Marcela V. Maus, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Hit the Ground Running: What You Need to Know About CAR T-Cell Therapy 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Overcoming a Critical Obstacle Towards Effective and Safe CAR T-Cell Therapeutics 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Engineering an Optimized Trimeric APRIL-Based CAR to Broaden Targetability of Multiple Myeloma 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood Cancers
    Infections the Main Cause of Nonrelapse Mortality After CAR-T for Blood CancersSeptember 4th, 2024
  • Damon Runyon Cancer Research Foundation Awards $4.8 Million to Exceptional Early-Career Scientists
    Damon Runyon Cancer Research Foundation Awards $4.8 Million to Exceptional Early-Career ScientistsAugust 28th, 2024
  • The Race to Supercharge Cancer-Fighting T Cells
    The Race to Supercharge Cancer-Fighting T CellsJanuary 25th, 2023
  • Join now to see all

Other Languages

  • Spanish